The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adults and adolescents with chronic spontaneous urticaria.
This article was originally published on MedicalXpress.com
FDA approves Dupixent for chronic spontaneous urticaria
You may also be interested in:
The Latest
PetVet Dx Revolutionizes Wildlife Conservation with AI and Molecular Diagnostics to Combat Incurable CWD in Deer and Elk
Chronic wasting disease (CWD), a devastating prion illness that affects North American cervids like deer and elk, poses a grave threat to their well-being and conservation efforts. Furthermore, it presents a potential risk of human […]
The Latest
Twelve Foot Massage Techniques To Try Today
In this article, we will introduce you to 12 incredibly effective foot massage techniques that will leave you feeling rejuvenated and relaxed. Foot massages aren’t just a luxury; they provide numerous health benefits, such as […]
The Latest
The Key to a Strong Relationship? Communication
Effective communication is the foundation of any strong, healthy relationship. This article will explore the key elements required to build better communication between partners. We’ll cover the importance of active listening, using empathy and understanding […]
Read More:
-
Karolinska Institutet researchers report that children born before 34 weeks of gestation show persistent deficits in cognitive abilities at ages 9 to 10. Impairments appear [...]
-
According to a study presented at the Pediatric Academic Societies (PAS) 2025 Meeting, held April 24–28 in Honolulu, children treated with primary care telehealth visits [...]
-
Pregnant women living with opioid use disorder (OUD) and their infants had significantly better health outcomes when treated with buprenorphine, according to a new study [...]
